Coamorphous repaglinide-saccharin with enhanced dissolution

International Journal of Pharmaceutics

Volumn 450, Issue 1-2, 2013, Pages 290-295

  Gao, Yuan ^a   Liao, Jiao ^a   Qi, Xuan ^a   Zhang, Jianjun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Coamorphous; Dissolution; Repaglinide; Saccharin; Supersaturation

Indexed keywords

AMINE; CARBONYL DERIVATIVE; HYDROGEN; REPAGLINIDE; SACCHARIN; WATER;

ARTICLE; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; DIFFRACTION; DRUG SOLUBILITY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; SOLUTION CRYSTALLIZATION; STOICHIOMETRY;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; HYPOGLYCEMIC AGENTS; PIPERIDINES; POWDER DIFFRACTION; SACCHARIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84878360280     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.032     Document Type: Article

References (33)

1. S. Basavoju, D. Boström, and S.P. Velaga Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization Pharm. Res. 25 2008 530 541
2. R. Chadha, S. Bhandari, P. Arora, and R. Chhikara Characterization, quantification and stability of differently prepared amorphous forms of some oral hypoglycaemic agents Pharm. Dev. Technol. 18 2013 504 514
3. C. Charcosset Membrane Processes in Biotechnologies and Pharmaceutics 2012 Elsevier Publisher UK pp. 307
4. M.L. Cheney, D.R. Weyna, N. Shan, M. Hanna, L. Wojias, and M.J. Zaworotko Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics J. Pharm. Sci. 100 2011 2172 2181
5. C.R. Culy, and B. Jarvis Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus Drugs 61 2001 1625 1660
6. N.S. Desai, D.M. Bramhane, and M.S. Nagarsenker Repaglinide-cyclodextrin complexes: preparation, characterization and in vivo evaluation of antihyperglycemic activity J. Incl. Phenom. Macrocycl. Chem. 70 2011 217 225
7. C.J. Dunn, and D. Faulds Nateglinide Drugs 60 2000 607 615
8. Y. Gao, J. Gao, Z. Liu, H. Kan, H. Zu, W. Sun, J. Zhang, and S. Qian Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals Int. J. Pharm. 438 2012 327 335
9. Y. Gao, H. Zu, and J. Zhang Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation J. Pharm. Pharmacol. 63 2011 483 490
10. V. Hatorp, S. Oliver, and C.A. Su Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers Int. J. Clin. Pharmacol. Ther. 36 1998 636 641
11. M.S. Jung, J.S. Kim, M.S. Kim, A. Alhalaweh, W. Cho, S.J. Hwang, and S.P. Velaga Bioavailability of indomethacin-saccharin cocrystals J. Pharm. Pharmacol. 62 2010 1560 1568
12. R. Kavitha, and A.A.H. Sathali Enhancement of solubility of repaglinide by solid dispersion technique Int. J. Chem. Sci. 10 2012 377 390
13. J.S. Kim, M.S. Kim, S.J. Jin, S. Lee, and S.J. Hwanq Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process Int. J. Pharm. 359 2008 211 219
14. K. Löbmann, R. Laitinen, H. Grohqanz, K.C. Gordon, and T. Rades Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen Mol. Pharm. 8 2011 1919 1928
15. Löbmann, K.; Laitinen, R.; Grohqanz, H.; Strachan, C.; Randes, T.; Gordon, K.C.; in press. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int. J. Pharm, http://dx.doi.org/10.1016/j.ijpharm. 2012.05.016.
16. K. Löbmann, C. Strachan, H. Grohqanz, T. Rades, O. Korhonen, and R. Laitinen Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions Eur. J. Pharm. Biopharm. 81 2012 159 169
17. Z. Mandić, and V. Gabelica Ionization, lipophilicity and solubility properties of repaglinide J. Pharm. Biomed. Anal. 41 2006 866 871
18. S. Maruyama, and H. Ooshima Crystallization behavior of taltirelin polymorphs in a mixture of water and methanol J. Cryst. Growth 212 2000 239 245
19. D.P. McNamara, S.L. Childs, J. Giordano, A. Iarriccio, J. Cassidy, M.S. Shet, R. Mannion, E. O'Donnell, and A. Park Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 23 2006 1888 1897
20. C. Nicolescu, C. Arama, A. Nedelcu, and C.M. Monciu Phase solubility studies of the inclusion complexes of repaglinide with β-cyclodextrin and β-cyclodextrin derivatives Farmacia 58 2010 620 628
21. A. Otte, Y. Zhang, M.T. Carvajal, and R. Pinal Milling induces disorder in crystalline griseofulvin and order in its amorphous counterpart CrystEngComm 14 2012 2560 2570
22. T. Purvis, M.E. Mattucci, M.T. Mrisp, K.P. Johnston, and R.O. Williams 3rd. Rapidly dissolving REPAGLINIDE powders produced by the ultra-rapid freezing process AAPS PharmSciTech 8 2007 E52 E60
23. L.J. Scott Repaglinide: a review of its use in type 2 diabetes mellitus Drugs 72 2012 249 272
24. F.G. Shi, H.Y. Tong, and J.D. Ayers Free energy barrier to nucleation of amorphous-to-crystalline transformation selects the scale of microstructure of crystallized materials Appl. Phys. Lett. 67 1995 350 352
25. 2 thin films Phys. Rev. Lett. 74 1995 4476 4478
26. P. Sinswat, M.E. Matteucci, K.P. Johnston, and R.O. Williams 3rd. Dissolution rates and supersaturation behavior of amorphous REPAGLINIDE particles produced by controlled precipitation J. Biomed. Nanotechnol. 3 2007 18 27
27. P. Sudhakar, S.V. Kumar, P. Vishweshwar, J.M. Babu, and K. Vyas Solid state structural studies of saccharin salts with some heterocyclic bases CrystEngComm 10 2008 996 1002
28. L.S. Taylor, and G. Zografi Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions Pharm. Res. 14 1997 1691 1698
29. P. Vishweshwar, J.A. McMahon, J.A. Bis, and M.J. Zaworotko Pharmaceutical co-crystals J. Pharm. Sci. 95 2006 499 516
30. B.H. Wolffenbuttel Repaglinide - a new compound for the treatment of patients with type 2 diabetes Neth. J. Med. 55 1999 229 234
31. T.X. Xiang, and B.D. Anderson Molecular dynamics simulation of amorphous indomethacin Mol. Pharm. 10 2013 102 114
32. S. Yamamura, H. Gotoh, Y. Sakamoto, and Y. Momose Physicochemical properties of amorphous precipitates of cimetidine-indomethacin binary system Eur. J. Pharm. Biopharm. 49 2000 259 265
33. W. Yang, K.P. Johnston, and R.O. Williams 3rd. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats Eur. J. Pharm. Biopharm. 75 2010 33 41